Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | ADK | P55263 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979098 | 0.84 | MAP4K4 (0.49) | MAPTINPPL1MEN1KMT2ATDP1 | |
| SCHEMBL2981349 | 0.81 | INPPL1 (0.57) | MAPTINPPL1MEN1KMT2ATDP1 | |
| SCHEMBL1582196 | 0.81 | MAP4K4 (0.49) | MAPTINPPL1MEN1KMT2ATDP1 | |
| SCHEMBL5034039 | 0.81 | MAPT (0.46) | MAPTINPPL1MEN1KMT2ATDP1 | |
| SCHEMBL710165 | 0.80 | CRHBP (0.53) | MAPTINPPL1MEN1KMT2ATDP1 | |
| SCHEMBL11224806 | 0.79 | INPPL1 (0.49) | MAPTINPPL1MEN1KMT2ATDP1 | |
| SCHEMBL2972043 | 0.78 | PDGFRB (0.49) | MAPTMEN1KMT2ATDP1LMNA | |
| SCHEMBL5036448 | 0.75 | DHFR (0.54) | MAPTINPPL1MEN1KMT2ATDP1 | |
| SCHEMBL10008911 | 0.75 | MAP4K4 (0.54) | MAPTMEN1KMT2ATDP1POLB | |
| SCHEMBL6311840 | 0.73 | MAPT (0.50) | MAPTMEN1KMT2ATDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| CN-100415746-C | Aminopyridine derivatives as inducible NO-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-09-03 | — | — | CN | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| CN-1856493-A | Aminopyridine derivatives as inducible NO-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1670798-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | Altana Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061496-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | NOS2, NOS1, NOS3 | MAPT 3074/4885INPPL1 2543/4885MEN1 4279/4885 |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | MAPT 3074/4885INPPL1 2543/4885MEN1 4279/4885 |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | NOS2, NOS1, NOS3 | MAPT 4149/4885INPPL1 1506/4885MEN1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.